» Articles » PMID: 34907233

Postoperative Proliferative Vitreoretinopathy Development is Linked to Vitreal CXCL5 Concentrations

Overview
Journal Sci Rep
Specialty Science
Date 2021 Dec 15
PMID 34907233
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The specific changes linked to de novo development of postoperative PVR have remained elusive and were the object of the underlying study. Vitreous fluid (VF) was obtained at the beginning of vitrectomy from 65 eyes that underwent vitrectomy for primary rhegmatogenous retinal detachment (RRD) without preoperative PVR. Eyes developing postoperative PVR within 6 months after re-attachment surgery were compared to those which did not regarding the preoperative concentrations of 43 cytokines and chemokines in the VF, using multiplex beads analysis. For all comparisons Holm's correction was applied in order to control for multiple comparisons. Twelve out of 65 eyes (18.5%) developed PVR postoperatively. While 12 of the chemokines and cytokines presented concentration differences on a statistical level of p < 0.05 (CXCL5, CCL11, CCL24, CCL26, GM-CSF, IFN-γ, CCL8, CCL7, MIF, MIG/CXCL9, CCL19, and CCL25), CXCL5 was the only cytokine with sufficiently robust difference in its VF concentrations to achieve significance in eyes developing postoperative PVR compared to eyes without PVR. CXCL5 may represent a potent biomarker for the de novo development of postoperative PVR. In line with its pathophysiological role in the development of PVR, it might serve as a basis for the development of urgently needed preventive options.

Citing Articles

Nano-Based Drug Approaches to Proliferative Vitreoretinopathy Instead of Standard Vitreoretinal Surgery.

Sorrentino F, Gardini L, Culiersi C, Fontana L, Musa M, DEsposito F Int J Mol Sci. 2024; 25(16).

PMID: 39201407 PMC: 11354910. DOI: 10.3390/ijms25168720.


Vitreous Olink proteomics reveals inflammatory biomarkers for diagnosis and prognosis of traumatic proliferative vitreoretinopathy.

Guo H, Wang T, Yu J, Shi Z, Liang M, Chen S Front Immunol. 2024; 15:1355314.

PMID: 38455059 PMC: 10917961. DOI: 10.3389/fimmu.2024.1355314.


Risk factors for proliferative vitreoretinopathy after retinal detachment surgery: A systematic review and meta-analysis.

Xiang J, Fan J, Wang J PLoS One. 2023; 18(10):e0292698.

PMID: 37903162 PMC: 10615281. DOI: 10.1371/journal.pone.0292698.


Proliferative vitreoretinopathy: an update on the current and emerging treatment options.

Desideri L, Artemiev D, Zandi S, Zinkernagel M, Anguita R Graefes Arch Clin Exp Ophthalmol. 2023; 262(3):679-687.

PMID: 37843566 PMC: 10907475. DOI: 10.1007/s00417-023-06264-1.


Nomogram for predicting non-proliferative vitreoretinopathy probability after vitrectomy in eyes with rhegmatogenous retinal detachment.

Gao Z, Wu P, Zhang J, Ke Z, Hu X, Zhang Z Int J Ophthalmol. 2023; 16(2):215-223.

PMID: 36816206 PMC: 9922634. DOI: 10.18240/ijo.2023.02.07.

References
1.
Schnyder-Candrian S, Strieter R, Kunkel S, Walz A . Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. J Leukoc Biol. 1995; 57(6):929-35. DOI: 10.1002/jlb.57.6.929. View

2.
Chaudhary R, Scott R, Wallace G, Berry M, Logan A, Blanch R . Inflammatory and Fibrogenic Factors in Proliferative Vitreoretinopathy Development. Transl Vis Sci Technol. 2020; 9(3):23. PMC: 7357815. DOI: 10.1167/tvst.9.3.23. View

3.
Kauffmann D, van Meurs J, Mertens D, Peperkamp E, Master C, Gerritsen M . Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994; 35(3):900-6. View

4.
Pfister I, Zandi S, Gerhardt C, Spindler J, Reichen N, Garweg J . Risks and Challenges in Interpreting Simultaneous Analyses of Multiple Cytokines. Transl Vis Sci Technol. 2020; 9(7):27. PMC: 7414671. DOI: 10.1167/tvst.9.7.27. View

5.
Garweg J, Tappeiner C, Halberstadt M . Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol. 2013; 58(4):321-9. DOI: 10.1016/j.survophthal.2012.12.004. View